Prostate cancer shake-up looms with new data from Pfizer, Astellas and Johnson & Johnson

Pfizer, Astellas and J&J envision a wide-open new field for patients whose prostate cancer hasn't yet spread, and they've got data that could open the gates. Next up: a high-stakes market scrum pitting Pfizer and Astellas' Xtandi against J&J's candidate apalutamide—and, potentially and crucially, generics of J&J's blockbuster Zytiga.Original Article